|
Market Closed -
Nasdaq
16:00:00 2026-01-06 EST
|
5-day change | 1st Jan Change | ||
| 221.38 USD | +0.03% |
|
-.--% | +0.22% |
| 01-08 | Cidara Therapeutics, Inc.(NasdaqCM:CDTX) dropped from Russell 2000 Value Benchmark | CI |
| 01-08 | Cidara Therapeutics, Inc.(NasdaqCM:CDTX) dropped from Russell 2500 Value Benchmark | CI |
| Market Cap | 6.96B 5.99B 5.63B 5.15B 9.63B 657B 9.65B 66.58B 25.83B 337B 26.13B 25.56B 1,086B | P/E 2023 |
-3.03x | P/E 2024 | -1.01x |
|---|---|---|---|---|---|
| Enterprise Value | 6.77B 5.83B 5.48B 5.01B 9.37B 639B 9.4B 64.79B 25.14B 328B 25.43B 24.88B 1,057B | EV / Sales 2023 |
0.64x | EV / Sales 2024 | 84.5x |
| Free-Float |
-
| Yield 2023 * |
-
| Yield 2024 | - |
Last Transcript : Cidara Therapeutics
| 1 day | +0.03% | ||
| Current year | +0.22% |
| Current year | 220.47 |  | 221.42 |
| 1 year | 61.1 | | 221.42 |
| 3 years | 10 | | 221.42 |
| 5 years | 8 | | 221.42 |
| 10 years | 8 | | 259 |
| Manager | Title | Age | Since |
|---|---|---|---|
Frank Karbe
DFI | Director of Finance/CFO | 58 | 2025-02-23 |
Corrina Pavetto
CTO | Chief Tech/Sci/R&D Officer | - | 2025-04-30 |
| Chief Tech/Sci/R&D Officer | - | 2025-04-30 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 1/7/26 | Issuer sale | Chief Financial Officer | 165,651 | 0.6532% | ||
| 1/7/26 | Issuer sale | Director | 35,375 | 0.1395% | ||
| 1/7/26 | Issuer sale | Chief Operating Officer | 241,829 | 0.9537% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 63.9M 54.99M 51.74M 47.26M 88.41M 6.03B 88.66M 611M 237M 3.1B 240M 235M 9.97B | 1.28M 1.1M 1.03M 943K 1.76M 120M 1.77M 12.2M 4.73M 61.76M 4.79M 4.68M 199M |
| Net income | -22.93M -19.73M -18.57M -16.96M -31.73M -2.17B -31.81M -219M -85.13M -1.11B -86.11M -84.23M -3.58B | -170M -146M -137M -126M -235M -16.03B -236M -1.62B -630M -8.23B -638M -624M -26.5B |
| Net Debt | -30.9M -26.59M -25.02M -22.85M -42.75M -2.92B -42.87M -296M -115M -1.5B -116M -114M -4.82B | -186M -160M -151M -138M -258M -17.58B -258M -1.78B -691M -9.02B -699M -684M -29.07B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- CDTX Stock
Select your edition
All financial news and data tailored to specific country editions
